ASST
Strive, Inc.
There isn't enough reported data to score ASST yet.
META
Meta Platforms, Inc.
META's fundamentals are mixed, but it looks cheap: trading at 21x earnings, below its usual 27x. Analysts expect earnings growth, though they disagree widely on how much.
ASST Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Weak | |
| Weak | |
| Strong |
ASST's revenue and balance sheet are currently healthy, but its profitability and cash flow are weak.
META Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
META's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
ASST PE Valuation
ASST has no meaningful PE right now: it lost money over the past year. If it returns to profit as analysts expect, today's price would be 6.0x next year's earnings.
META PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 19x | $624 | — |
| Cheap | 21x | $613 | -1.7% |
| Current | 21x | $624 | — |
| Fair | 27x | $803 | +29% |
| Expensive | 32x | $934 | +50% |
Historical ranges are pointers, not guarantees.
META's PE is in its cheap range at 21x. If earnings grow as analysts expect, today's price would be 19x next year's earnings.
ASST Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| -- | |
| Limited | |
| Low |
Analysts expect ASST to return to profit, with revenue growing. However, they disagree widely on these estimates.
META Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Strong growth | |
| Strongly weakening | |
| Moderate | |
| Low |
Analysts expect earnings and revenue growth for META, but weaker profitability. However, they disagree widely on these estimates.
ASST Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.73 | — |
| Q3 2026 | -$183.86 | -$41.36 |
| Q2 2026 | -$313.10 | -$286.40 |
| Q1 2026 | -$312.73 | -$277.83 |
| Q4 2025 | -$310.80 | -$242.50 |
| Q3 2025 | -$142.50 | -$78.70 |
| Q2 2025 | -$26.70 | +$37.90 |
| Q1 2025 | -$34.90 | +$28.10 |
| Q4 2024 | -$68.30 | -$32.30 |
ASST lost $183.86 per share over the past year, a bigger loss than the year before.
META Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $32.16 | +9.7% |
| Q3 2026 | $29.32 | +30% |
| Q2 2026 | $26.54 | -3.7% |
| Q1 2026 | $27.50 | +7.5% |
| Q4 2025 | $23.49 | -1.6% |
| Q3 2025 | $22.58 | +6.5% |
| Q2 2025 | $27.56 | +41% |
| Q1 2025 | $25.58 | +47% |
| Q4 2024 | $23.86 | +60% |
META has the edge over ASST on earnings quality, reporting a profit while its opponent remains loss making.
ASST Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.7M | +75% |
| Q2 2026 | $2.9M | +1597% |
| Q1 2026 | $2.8M | +1516% |
| Q4 2025 | $1.5M | +611% |
| Q3 2025 | $1.5M | +660% |
| Q2 2025 | $173.3K | +86% |
| Q1 2025 | $170.7K | +37% |
| Q4 2024 | $212.8K | +163% |
ASST has the edge over META on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 18844% | +20355 points |
| Q2 2026 | -8781% | -7227 points |
| Q1 2026 | -11346% | -10376 points |
| Q4 2025 | -15948% | -15020 points |
| Q3 2025 | -1511% | -863 points |
| Q2 2025 | -1554% | +303 points |
| Q1 2025 | -970% | +141 points |
| Q4 2024 | -928% | +739 points |
ASST has the edge over META on profitability, with a higher operating margin.
META Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $64.6B | +26% |
| Q2 2026 | $60.8B | +28% |
| Q1 2026 | $56.3B | +33% |
| Q4 2025 | $59.9B | +24% |
| Q3 2025 | $51.2B | +26% |
| Q2 2025 | $47.5B | +22% |
| Q1 2025 | $42.3B | +16% |
| Q4 2024 | $48.4B | +21% |
META's revenue has grown year over year for 15 quarters in a row: $64.6B last quarter, up 26% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | -20 points |
| Q2 2026 | 31% | -12 points |
| Q1 2026 | 41% | -0.9 points |
| Q4 2025 | 41% | -7 points |
| Q3 2025 | 40% | -2.7 points |
| Q2 2025 | 43% | +5 points |
| Q1 2025 | 41% | +3.6 points |
| Q4 2024 | 48% | +7.4 points |
META's operating margin was 20% last quarter, down 20 points from the same quarter a year ago, near the bottom of its range since 2019.
ASST Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$10.1M | +$18.8M |
| Q3 2025 | -$28.9M | -$27.8M |
| Q2 2024 | -$1.3M | -$146.2K |
| Q1 2024 | -$1.1M | -$224.6K |
| Q4 2023 | -$860.1K | -$650.5K |
| Q2 2023 | -$1.1M | -$917.5K |
| Q1 2023 | -$829.9K | -$754.9K |
| Q4 2022 | -$209.6K | -5434% |
ASST has burned cash in almost every quarter: −$75M over the past year, against −$32M the year before.
META Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -110% |
| Q2 2026 | $1.7B | -81% |
| Q1 2026 | $13.2B | +19% |
| Q4 2025 | $14.8B | +9.3% |
| Q3 2025 | $11.2B | -32% |
| Q2 2025 | $9B | -19% |
| Q1 2025 | $11.1B | -14% |
| Q4 2024 | $13.6B | +16% |
META has the edge over ASST on cash generation, producing positive trailing cash flow while its opponent burns cash.
ASST Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +20% | +15.3M shares |
| 1 year | +5331% | +88.9M shares |
| 3 years | +65691% | +90.4M shares |
| 5 years | +1478019% | +90.5M shares |
ASST has 91M diluted shares, up 5331% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2025 | $500,000 |
| Q4 2022 | — |
| Q3 2022 | — |
| Q2 2022 | — |
| Q1 2022 | — |
| Q4 2021 | — |
META Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +7M shares |
| 1 year | 0% | +1M shares |
| 3 years | -2.6% | -68M shares |
| 5 years | -10% | -286M shares |
| Available history | -11% | -303M shares |
META has the edge over ASST on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | — |
| Q2 2026 | — |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | $3.3B |
| Q2 2025 | $10.2B |
| Q1 2025 | $12.8B |
| Q4 2024 | — |
META hasn't bought back shares in the past year.
ASST Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2021 | -1.7x | Net Cash |
ASST has more cash than debt.
META Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 0.7x | Very low |
| Q2 2026 | 0.6x | Very low |
| Q1 2026 | 0.3x | Very low |
| Q4 2025 | 0.2x | Very low |
| Q3 2025 | 0.2x | Very low |
| Q2 2025 | 0.2x | Very low |
| Q1 2025 | 0.0x | Very low |
| Q4 2024 | -0.2x | Net Cash |
META's net debt is less than a year of its operating earnings (EBITDA).
ASST Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 50.8 | Neutral |
| Stochastic | 51.4 | Neutral |
ASST's weekly RSI is 51 (neutral) and its Stochastic is 51 (neutral).
META Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.2 | Neutral |
| Stochastic | 33.7 | Neutral |
META's weekly RSI is 48 (neutral) and its Stochastic is 34 (neutral).
ASST PE vs Communication Services Sector
ASST has no meaningful PE right now: it lost money over the past year.
META PE vs Communication Services Sector
| Metric | META | Sector median | Relative |
|---|---|---|---|
| PE | 21x | 16x | 29% above |
| PE % | 18 | 26 | 8 pts below |
META is trading at 21x earnings, a 29% premium to the Communication Services sector's median of 16x.
ASST Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $25.8 | 14% below |
| 20 week MA | $20.8 | 7% above |
| 50 week MA | $16.8 | 32% above |
| 100 week MA | $35.7 | 38% below |
ASST has stronger trend alignment. ASST is above 2 of 4 weekly averages versus META above 1 of 5.
META Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $674.9 | 7.6% below |
| 20 week MA | $634.5 | 1.7% below |
| 50 week MA | $630.8 | 1.1% below |
| 100 week MA | $647.8 | 3.7% below |
| 200 week MA | $517.5 | 21% above |
META has fallen below most of its moving averages, though it's still 21% above its 200-week average.
ASST Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2023 | $355.0 | $63.9 | -82% |
| 2024 | $63.9 | $9.32 | -85% |
| 2025 | $9.32 | $16.3 | +75% |
| 2026 YTD | $16.3 | $22.3 | +37% |
ASST has the edge over META on returns for 2026, with the stronger performance.
META Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $208.1 | $267.4 | +28% |
| 2021 | $267.4 | $335.2 | +25% |
| 2022 | $335.2 | $118.0 | -65% |
| 2023 | $118.0 | $354.0 | +200% |
| 2024 | $354.0 | $599.8 | +69% |
| 2025 | $599.8 | $663.3 | +11% |
| 2026 YTD | $663.3 | $623.6 | -6% |
META's yearly returns have swung widely, from +200% in 2023 to −65% in 2022. It's down 6% so far in 2026.